Lee Y W, Yaksh T L
Department of Anesthesiology, University of California, San Diego, USA.
J Pharmacol Exp Ther. 1996 Jun;277(3):1642-8.
The effects of intrathecally delivered adenosine agonists on allodynia induced by L5/L6 spinal nerve ligation in rats with lumbar intrathecal catheters were examined. Tactile allodynia was assessed by measuring the threshold for evoking withdrawal of the lesioned hind paw with calibrated von Frey hairs. Intrathecal administration of the A1 adenosine selective agonist, N6-(2-phenylisopropyl)-adenosine R-(-)isomer (R-PIA), produced a dose-dependent (0.3-3 nmol; ED50 = 0.6 nmol) antiallodynic action and evoked a delayed motor weakness at a dosage of 30 nmol. Intrathecal administration of the A2 adenosine selective agonist, CGS 21680 {2-p-(2-carboxyethyl) phenethylamino-5'-N-ethylcarboxamido adenosine hydrochloride}, also produced a dose-dependent reduction in allodynia (2-40 nmol; ED50 = 15 nmol), but this effect was associated at 40 nmol after a short interval with prominent hind limb weakness. Intrathecal pretreatment with A1/A2 adenosine antagonists, caffeine (20 mumol) and 8-sulfophenyltheophylline (60 nmol), blocked antiallodynic actions of R-PIA (1 nmol) and CGS 21680 (40 nmol). Intrathecal pretreatment with the A1 adenosine-selective antagonist, 8-cyclopentyl-1,3-dimethylxanthine (3 nmol), blocked the antiallodynic effect of R-PIA (1 nmol), but even a dose as high as 10 nmol did not block the effect of CGS 21680 (40 nmol). The A2 adenosine-selective antagonist, 3, 7-dimethyl-1-propargylxanthine (3 nmol), prevented the antiallodynic effects of R-PIA (1 nmol) and CGS 21680 (40 nmol). Pretreatment with caffeine (20 mumol), 8-sulfophenyltheophylline (60 nmol) and 3,7-dimethyl-1-propargylxanthine (3 nmol) prevented the motor dysfunction induced by R-PIA (30 nmol) and CGS 21680 (40 nmol), but 8-cyclopentyl-1,3-dimethylxanthine (3 or 10 nmol) did not. Based on these effects, we hypothesize that the antiallodynic effects are mediated through the activation of spinal A1 adenosine receptors and motor dysfunction effects are mediated through A2 adenosine receptors.
研究了鞘内注射腺苷激动剂对腰段鞘内置管大鼠L5/L6脊神经结扎诱导的异常性疼痛的影响。通过用校准的von Frey毛发测量诱发损伤后爪退缩的阈值来评估触觉异常性疼痛。鞘内注射A1腺苷选择性激动剂N6-(2-苯异丙基)-腺苷R-(-)异构体(R-PIA)产生剂量依赖性(0.3 - 3 nmol;ED50 = 0.6 nmol)的抗异常性疼痛作用,并在30 nmol剂量时诱发延迟性运动无力。鞘内注射A2腺苷选择性激动剂CGS 21680 {2-p-(2-羧乙基)苯乙胺-5'-N-乙基羧酰胺腺苷盐酸盐}也产生剂量依赖性的异常性疼痛减轻(2 - 40 nmol;ED50 = 15 nmol),但在40 nmol剂量时,短时间后这种作用与明显的后肢无力有关。鞘内用A1/A2腺苷拮抗剂咖啡因(20 μmol)和8-磺基苯基茶碱(60 nmol)预处理可阻断R-PIA(1 nmol)和CGS 21680(40 nmol)的抗异常性疼痛作用。鞘内用A1腺苷选择性拮抗剂8-环戊基-1,3-二甲基黄嘌呤(3 nmol)预处理可阻断R-PIA(1 nmol)的抗异常性疼痛作用,但即使高达10 nmol的剂量也不能阻断CGS 21680(40 nmol)的作用。A2腺苷选择性拮抗剂3,7-二甲基-1-炔丙基黄嘌呤(3 nmol)可预防R-PIA(1 nmol)和CGS 21680(40 nmol)的抗异常性疼痛作用。用咖啡因(20 μmol)、8-磺基苯基茶碱(60 nmol)和3,7-二甲基-1-炔丙基黄嘌呤(3 nmol)预处理可预防R-PIA(30 nmol)和CGS 21680(40 nmol)诱导的运动功能障碍,但8-环戊基-1,3-二甲基黄嘌呤(3或10 nmol)则不能。基于这些作用,我们推测抗异常性疼痛作用是通过激活脊髓A1腺苷受体介导的,而运动功能障碍作用是通过A2腺苷受体介导的。